TG Therapeutics to Present BRIUMVI Data at AAN 2026, Highlighting Real-World Efficacy
Event summary
- TG Therapeutics will present two posters on BRIUMVI (ublituximab) at the AAN 2026 meeting, focusing on real-world clinical experience and safety data.
- Presentations will occur on April 21, 2026, covering the ENABLE Phase 4 study and ENHANCE study updates.
- BRIUMVI is approved in the U.S. for relapsing forms of multiple sclerosis (RMS) and in several countries for RMS with active disease.
- Key safety concerns include infusion reactions, infections, and potential liver injury.
The big picture
TG Therapeutics is positioning BRIUMVI as a key player in the relapsing MS market, leveraging real-world data to strengthen its clinical profile. The focus on safety and tolerability comes as the company seeks to expand its commercial footprint in a segment dominated by established therapies. The AAN 2026 presentations will be critical in shaping investor and physician perceptions of BRIUMVI's long-term potential.
What we're watching
- Clinical Efficacy
- Whether real-world data from the ENABLE study will reinforce BRIUMVI's value proposition in RMS treatment.
- Safety Profile
- How the modified dosing regimen in the ENHANCE study impacts BRIUMVI's safety and tolerability.
- Market Positioning
- The pace at which TG Therapeutics can differentiate BRIUMVI in a competitive MS treatment landscape.
Related topics